Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 251

2.

Calf Clinical Model of Cryptosporidiosis for Efficacy Evaluation of Therapeutics.

Riggs MW, Schaefer DA.

Methods Mol Biol. 2020;2052:253-282. doi: 10.1007/978-1-4939-9748-0_15.

PMID:
31452167
3.

Impact of depression on speech perception in noise.

Xie Z, Zinszer BD, Riggs M, Beevers CG, Chandrasekaran B.

PLoS One. 2019 Aug 15;14(8):e0220928. doi: 10.1371/journal.pone.0220928. eCollection 2019.

4.

Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer.

Lu D, Li C, Riggs M, Polhamus D, French J, Agarwal P, Chen SC, Vadhavkar S, Patre M, Strasak A, Quartino A, Jin JY, Girish S.

Cancer Chemother Pharmacol. 2019 Jul;84(1):175-185. doi: 10.1007/s00280-019-03852-z. Epub 2019 May 17.

PMID:
31102024
5.

Associations between cardiopulmonary resuscitation (CPR) knowledge, self-efficacy, training history and willingness to perform CPR and CPR psychomotor skills: A systematic review.

Riggs M, Franklin R, Saylany L.

Resuscitation. 2019 May;138:259-272. doi: 10.1016/j.resuscitation.2019.03.019. Epub 2019 Mar 27. Review.

PMID:
30928504
6.

A Systematic Review of Large Agriculture Vehicles Use and Crash Incidents on Public Roads.

Franklin RC, King JC, Riggs M.

J Agromedicine. 2019 Mar 16:1-14. doi: 10.1080/1059924X.2019.1593275. [Epub ahead of print]

PMID:
30879394
7.

Error patterns of native and non-native listeners' perception of speech in noise.

Zinszer BD, Riggs M, Reetzke R, Chandrasekaran B.

J Acoust Soc Am. 2019 Feb;145(2):EL129. doi: 10.1121/1.5087271.

8.

Pharmacometrics and systems pharmacology for metabolic bone diseases.

Riggs MM, Cremers S.

Br J Clin Pharmacol. 2019 Jun;85(6):1136-1146. doi: 10.1111/bcp.13881. Epub 2019 Feb 28. Review.

PMID:
30690761
9.

When Learn/Confirm Leads to Expand/Understand: The Expanding Role of Quantitative Systems Pharmacology in the Betterment of Therapeutics Development.

Riggs MM.

Clin Pharmacol Ther. 2019 Mar;105(3):558-560. doi: 10.1002/cpt.1287. Epub 2018 Dec 18. No abstract available.

PMID:
30565207
10.

A Multisectoral Emergency Response Approach to a Cholera Outbreak in Zambia: October 2017-February 2018.

Kapata N, Sinyange N, Mazaba ML, Musonda K, Hamoonga R, Kapina M, Zyambo K, Malambo W, Yard E, Riggs M, Narra R, Murphy J, Brunkard J, Azman AS, Monze N, Malama K, Mulwanda J, Mukonka VM.

J Infect Dis. 2018 Oct 15;218(suppl_3):S181-S183. doi: 10.1093/infdis/jiy490. No abstract available.

11.

Supporting the Writing Productivity of Biomedical Graduate Students: An Integrated, Structured Writing Intervention.

Gardner SA, Salto LM, Riggs ML, Casiano CA, De Leon M.

CBE Life Sci Educ. 2018 Sep;17(3):ar45. doi: 10.1187/cbe.16-12-0350.

12.

The Eyes Do not Lie: A Case of Bilateral Subconjunctival Hemorrhages and Orbital Hematoma Postpartum.

Riggs MJ, Coston NH, Teneyuque NR, Keyser EA.

Mil Med. 2019 Jan 1;184(1-2):e272-e274. doi: 10.1093/milmed/usy157.

PMID:
30010997
13.

Modelling Cryptosporidium infection in human small intestinal and lung organoids.

Heo I, Dutta D, Schaefer DA, Iakobachvili N, Artegiani B, Sachs N, Boonekamp KE, Bowden G, Hendrickx APA, Willems RJL, Peters PJ, Riggs MW, O'Connor R, Clevers H.

Nat Microbiol. 2018 Jul;3(7):814-823. doi: 10.1038/s41564-018-0177-8. Epub 2018 Jun 25.

14.

Cholera Epidemic - Lusaka, Zambia, October 2017-May 2018.

Sinyange N, Brunkard JM, Kapata N, Mazaba ML, Musonda KG, Hamoonga R, Kapina M, Kapaya F, Mutale L, Kateule E, Nanzaluka F, Zulu J, Musyani CL, Winstead AV, Davis WW, N'cho HS, Mulambya NL, Sakubita P, Chewe O, Nyimbili S, Onwuekwe EVC, Adrien N, Blackstock AJ, Brown TW, Derado G, Garrett N, Kim S, Hubbard S, Kahler AM, Malambo W, Mintz E, Murphy J, Narra R, Rao GG, Riggs MA, Weber N, Yard E, Zyambo KD, Bakyaita N, Monze N, Malama K, Mulwanda J, Mukonka VM.

MMWR Morb Mortal Wkly Rep. 2018 May 18;67(19):556-559. doi: 10.15585/mmwr.mm6719a5.

15.

Perspective on the State of Pharmacometrics and Systems Pharmacology Integration.

Trame MN, Riggs M, Biliouris K, Marathe D, Mettetal J, Post TM, Rizk ML, Visser SAG, Musante CJ.

CPT Pharmacometrics Syst Pharmacol. 2018 Oct;7(10):617-620. doi: 10.1002/psp4.12313. Epub 2018 Aug 21.

16.

Management of highly differentiated thyroid follicular carcinoma of ovarian origin with a minimally invasive approach.

Riggs MJ, Kluesner JK, Miller CR.

Gynecol Oncol Rep. 2018 Apr 19;24:87-89. doi: 10.1016/j.gore.2018.04.008. eCollection 2018 May.

17.

Status of HIV Epidemic Control Among Adolescent Girls and Young Women Aged 15-24 Years - Seven African Countries, 2015-2017.

Brown K, Williams DB, Kinchen S, Saito S, Radin E, Patel H, Low A, Delgado S, Mugurungi O, Musuka G, Tippett Barr BA, Nwankwo-Igomu EA, Ruangtragool L, Hakim AJ, Kalua T, Nyirenda R, Chipungu G, Auld A, Kim E, Payne D, Wadonda-Kabondo N, West C, Brennan E, Deutsch B, Worku A, Jonnalagadda S, Mulenga LB, Dzekedzeke K, Barradas DT, Cai H, Gupta S, Kamocha S, Riggs MA, Sachathep K, Kirungi W, Musinguzi J, Opio A, Biraro S, Bancroft E, Galbraith J, Kiyingi H, Farahani M, Hladik W, Nyangoma E, Ginindza C, Masangane Z, Mhlanga F, Mnisi Z, Munyaradzi P, Zwane A, Burke S, Kayigamba FB, Nuwagaba-Biribonwoha H, Sahabo R, Ao TT, Draghi C, Ryan C, Philip NM, Mosha F, Mulokozi A, Ntigiti P, Ramadhani AA, Somi GR, Makafu C, Mugisha V, Zelothe J, Lavilla K, Lowrance DW, Mdodo R, Gummerson E, Stupp P, Thin K, Frederix K, Davia S, Schwitters AM, McCracken SD, Duong YT, Hoos D, Parekh B, Justman JE, Voetsch AC.

MMWR Morb Mortal Wkly Rep. 2018 Jan 12;67(1):29-32. doi: 10.15585/mmwr.mm6701a6.

18.

Population Pharmacokinetic- Pharmacodynamic Analysis to Characterize the Effect of Empagliflozin on Renal Glucose Threshold in Patients With Type 1 Diabetes Mellitus.

Mondick J, Riggs M, Kaspers S, Soleymanlou N, Marquard J, Nock V.

J Clin Pharmacol. 2018 May;58(5):640-649. doi: 10.1002/jcph.1051. Epub 2017 Dec 18.

PMID:
29251772
19.

Utility of Single-Cell Genomics in Diagnostic Evaluation of Prostate Cancer.

Alexander J, Kendall J, McIndoo J, Rodgers L, Aboukhalil R, Levy D, Stepansky A, Sun G, Chobardjiev L, Riggs M, Cox H, Hakker I, Nowak DG, Laze J, Llukani E, Srivastava A, Gruschow S, Yadav SS, Robinson B, Atwal G, Trotman LC, Lepor H, Hicks J, Wigler M, Krasnitz A.

Cancer Res. 2018 Jan 15;78(2):348-358. doi: 10.1158/0008-5472.CAN-17-1138. Epub 2017 Nov 27.

20.

A model of fracture risk used to examine the link between bone mineral density and the impact of different therapeutic mechanisms on fracture outcomes in patients with osteoporosis.

Eudy-Byrne RJ, Gillespie W, Riggs MM, Gastonguay MR.

J Pharmacokinet Pharmacodyn. 2017 Dec;44(6):599-609. doi: 10.1007/s10928-017-9551-z. Epub 2017 Oct 28.

PMID:
29081020
21.

Advances in bumped kinase inhibitors for human and animal therapy for cryptosporidiosis.

Hulverson MA, Choi R, Arnold SLM, Schaefer DA, Hemphill A, McCloskey MC, Betzer DP, Müller J, Vidadala RSR, Whitman GR, Rivas KL, Barrett LK, Hackman RC, Love MS, McNamara CW, Shaughnessy TK, Kondratiuk A, Kurnick M, Banfor PN, Lynch JJ, Freiberg GM, Kempf DJ, Maly DJ, Riggs MW, Ojo KK, Van Voorhis WC.

Int J Parasitol. 2017 Oct;47(12):753-763. doi: 10.1016/j.ijpara.2017.08.006. Epub 2017 Sep 9.

22.

Population pharmacokinetics and exposure-response of trastuzumab emtansine in advanced breast cancer previously treated with ≥2 HER2-targeted regimens.

Chen SC, Quartino A, Polhamus D, Riggs M, French J, Wang X, Vadhavkar S, Smitt M, Hoersch S, Strasak A, Jin JY, Girish S, Li C.

Br J Clin Pharmacol. 2017 Dec;83(12):2767-2777. doi: 10.1111/bcp.13381. Epub 2017 Sep 3.

23.

Necessity of Bumped Kinase Inhibitor Gastrointestinal Exposure in Treating Cryptosporidium Infection.

Arnold SLM, Choi R, Hulverson MA, Schaefer DA, Vinayak S, Vidadala RSR, McCloskey MC, Whitman GR, Huang W, Barrett LK, Ojo KK, Fan E, Maly DJ, Riggs MW, Striepen B, Van Voorhis WC.

J Infect Dis. 2017 Jul 1;216(1):55-63. doi: 10.1093/infdis/jix247.

24.

5-Aminopyrazole-4-Carboxamide-Based Compounds Prevent the Growth of Cryptosporidium parvum.

Huang W, Choi R, Hulverson MA, Zhang Z, McCloskey MC, Schaefer DA, Whitman GR, Barrett LK, Vidadala RSR, Riggs MW, Maly DJ, Van Voorhis WC, Ojo KK, Fan E.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00020-17. doi: 10.1128/AAC.00020-17. Print 2017 Aug.

25.

Model-based meta-analysis for comparing Vitamin D2 and D3 parent-metabolite pharmacokinetics.

Ocampo-Pelland AS, Gastonguay MR, Riggs MM.

J Pharmacokinet Pharmacodyn. 2017 Aug;44(4):375-388. doi: 10.1007/s10928-017-9525-1. Epub 2017 May 2.

PMID:
28466367
26.

Bumped-Kinase Inhibitors for Cryptosporidiosis Therapy.

Hulverson MA, Vinayak S, Choi R, Schaefer DA, Castellanos-Gonzalez A, Vidadala RSR, Brooks CF, Herbert GT, Betzer DP, Whitman GR, Sparks HN, Arnold SLM, Rivas KL, Barrett LK, White AC Jr, Maly DJ, Riggs MW, Striepen B, Van Voorhis WC, Ojo KK.

J Infect Dis. 2017 Apr 15;215(8):1275-1284. doi: 10.1093/infdis/jix120. Erratum in: J Infect Dis. 2018 Jan 4;217(2):340.

27.

Extended-spectrum antiprotozoal bumped kinase inhibitors: A review.

Van Voorhis WC, Doggett JS, Parsons M, Hulverson MA, Choi R, Arnold SLM, Riggs MW, Hemphill A, Howe DK, Mealey RH, Lau AOT, Merritt EA, Maly DJ, Fan E, Ojo KK.

Exp Parasitol. 2017 Sep;180:71-83. doi: 10.1016/j.exppara.2017.01.001. Epub 2017 Jan 5. Review.

28.

Novel Bumped Kinase Inhibitors Are Safe and Effective Therapeutics in the Calf Clinical Model for Cryptosporidiosis.

Schaefer DA, Betzer DP, Smith KD, Millman ZG, Michalski HC, Menchaca SE, Zambriski JA, Ojo KK, Hulverson MA, Arnold SL, Rivas KL, Vidadala RS, Huang W, Barrett LK, Maly DJ, Fan E, Van Voorhis WC, Riggs MW.

J Infect Dis. 2016 Dec 15;214(12):1856-1864. Epub 2016 Oct 17.

29.
30.

Maximizing retention in long-term clinical trials of a weight loss agent: use of a dietitian support team.

Delahanty LM, Riggs M, Klioze SS, Chew RD, England RD, Digenio A.

Obes Sci Pract. 2016 Sep;2(3):256-265. Epub 2016 Aug 2.

31.

Population Pharmacokinetics and Exposure-Response (Efficacy and Safety/Tolerability) of Empagliflozin in Patients with Type 2 Diabetes.

Baron KT, Macha S, Broedl UC, Nock V, Retlich S, Riggs M.

Diabetes Ther. 2016 Sep;7(3):455-71. doi: 10.1007/s13300-016-0174-y. Epub 2016 Jun 16.

32.

Corrigendum: Genome-wide copy number analysis of single cells.

Baslan T, Kendall J, Rodgers L, Cox H, Riggs M, Stepansky A, Troge J, Ravi K, Esposito D, Lakshmi B, Wigler M, Navin N, Hicks J.

Nat Protoc. 2016 Mar;11(3):616. doi: 10.1038/nprot0316.616b. Epub 2016 Feb 25. No abstract available.

PMID:
26914320
33.

Model-based meta-analysis for development of a population-pharmacokinetic (PPK) model for Vitamin D3 and its 25OHD3 metabolite using both individual and arm-level data.

Ocampo-Pelland AS, Gastonguay MR, French JF, Riggs MM.

J Pharmacokinet Pharmacodyn. 2016 Apr;43(2):191-206. doi: 10.1007/s10928-016-9465-1. Epub 2016 Feb 12.

PMID:
26872884
34.

Mixed-effects modelling to quantify the effect of empagliflozin on renal glucose reabsorption in patients with type 2 diabetes.

Mondick J, Riggs M, Sasaki T, Sarashina A, Broedl UC, Retlich S.

Diabetes Obes Metab. 2016 Mar;18(3):241-8. doi: 10.1111/dom.12597. Epub 2016 Jan 15.

PMID:
26511213
35.

Protective effect of HLA-DQB1 alleles against alloimmunization in patients with sickle cell disease.

Tatari-Calderone Z, Gordish-Dressman H, Fasano R, Riggs M, Fortier C, Campbell AD, Charron D, Gordeuk VR, Luban NLC, Vukmanovic S, Tamouza R.

Hum Immunol. 2016 Jan;77(1):35-40. doi: 10.1016/j.humimm.2015.10.010. Epub 2015 Oct 22.

36.

Connecting the Dots: Linking Osteocyte Activity and Therapeutic Modulation of Sclerostin by Extending a Multiscale Systems Model.

Eudy RJ, Gastonguay MR, Baron KT, Riggs MM.

CPT Pharmacometrics Syst Pharmacol. 2015 Sep;4(9):527-36. doi: 10.1002/psp4.12013. Epub 2015 Sep 11.

37.

FDA Advisory Meeting Clinical Pharmacology Review Utilizes a Quantitative Systems Pharmacology (QSP) Model: A Watershed Moment?

Peterson MC, Riggs MM.

CPT Pharmacometrics Syst Pharmacol. 2015 Mar;4(3):e00020. doi: 10.1002/psp4.20. Epub 2015 Mar 12.

38.

Friendship chemistry: An examination of underlying factors.

Campbell K, Holderness N, Riggs M.

Soc Sci J. 2015 Jun;52(2):239-247.

39.

A Priori Identifiability of Target-Mediated Drug Disposition Models and Approximations.

Eudy RJ, Riggs MM, Gastonguay MR.

AAPS J. 2015 Sep;17(5):1280-4. doi: 10.1208/s12248-015-9795-8. Epub 2015 Jun 16.

40.

Two dose-ranging studies with PF-04937319, a systemic partial activator of glucokinase, as add-on therapy to metformin in adults with type 2 diabetes.

Amin NB, Aggarwal N, Pall D, Paragh G, Denney WS, Le V, Riggs M, Calle RA.

Diabetes Obes Metab. 2015 Aug;17(8):751-9. doi: 10.1111/dom.12474. Epub 2015 May 11.

PMID:
25885172
41.

Optimizing sparse sequencing of single cells for highly multiplex copy number profiling.

Baslan T, Kendall J, Ward B, Cox H, Leotta A, Rodgers L, Riggs M, D'Italia S, Sun G, Yong M, Miskimen K, Gilmore H, Saborowski M, Dimitrova N, Krasnitz A, Harris L, Wigler M, Hicks J.

Genome Res. 2015 May;25(5):714-24. doi: 10.1101/gr.188060.114. Epub 2015 Apr 9.

42.

Resistance to mate guarding scale in women: psychometric properties.

Cousins AJ, Fugère MA, Riggs ML.

Evol Psychol. 2015 Feb 3;13(1):106-28.

PMID:
25647785
43.

The effects of simultaneous exercise and psychotherapy on depressive symptoms in inpatient, psychiatric older adults.

Jacquart SD, Marshak HH, Dos Santos H, Luu SM, Berk LS, McMahon PT, Riggs M.

Adv Mind Body Med. 2014 Fall;28(4):8-17.

PMID:
25590292
44.

The secreted effector protein EspZ is essential for virulence of rabbit enteropathogenic Escherichia coli.

Wilbur JS, Byrd W, Ramamurthy S, Ledvina HE, Khirfan K, Riggs MW, Boedeker EC, Vedantam G, Viswanathan VK.

Infect Immun. 2015 Mar;83(3):1139-49. doi: 10.1128/IAI.02876-14. Epub 2015 Jan 5.

45.

An interview with Marion Riggs on the Student Society for Stem Cell Research.

Riggs M.

Stem Cells Dev. 2014 Dec;23 Suppl 1:7-9. doi: 10.1089/scd.2014.0417. No abstract available.

46.

Concurrent transcriptional profiling of Dirofilaria immitis and its Wolbachia endosymbiont throughout the nematode life cycle reveals coordinated gene expression.

Luck AN, Evans CC, Riggs MD, Foster JM, Moorhead AR, Slatko BE, Michalski ML.

BMC Genomics. 2014 Nov 29;15:1041. doi: 10.1186/1471-2164-15-1041.

47.

Underrepresented minority high school and college students report STEM-pipeline sustaining gains after participating in the Loma Linda University Summer Health Disparities Research Program.

Salto LM, Riggs ML, Delgado De Leon D, Casiano CA, De Leon M.

PLoS One. 2014 Sep 24;9(9):e108497. doi: 10.1371/journal.pone.0108497. eCollection 2014.

48.

Does Insurance Matter? Implementing Dialectical Behavior Therapy with Two Groups of Youth Engaged in Deliberate Self-harm.

James S, Freeman KR, Mayo D, Riggs ML, Morgan JP, Schaepper MA, Montgomery SB.

Adm Policy Ment Health. 2015 Jul;42(4):449-61. doi: 10.1007/s10488-014-0588-7.

49.

Exposure-response modelling for empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes.

Riggs MM, Seman LJ, Staab A, MacGregor TR, Gillespie W, Gastonguay MR, Woerle HJ, Macha S.

Br J Clin Pharmacol. 2014 Dec;78(6):1407-18. doi: 10.1111/bcp.12453.

50.

Multicenter validation of urinary CXCL9 as a risk-stratifying biomarker for kidney transplant injury.

Hricik DE, Nickerson P, Formica RN, Poggio ED, Rush D, Newell KA, Goebel J, Gibson IW, Fairchild RL, Riggs M, Spain K, Ikle D, Bridges ND, Heeger PS; CTOT-01 consortium.

Am J Transplant. 2013 Oct;13(10):2634-44. doi: 10.1111/ajt.12426. Epub 2013 Aug 22.

Supplemental Content

Support Center